A personalized strategy of dose-escalated radiotherapy (RT) for bladder cancer had a low rate of severe late toxicity and ...

As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a ...

We’ve rounded up the best, expert-recommended products to treat hyperpigmentation in dark skin, including cleansers, serums, ...

Roche (RHHBY) has received FDA approval for its drug Itovebi in combination with two other drugs for the treatment of breast ...

With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K ...

Novartis' Piqray/Vijoice (alpelisib) is the only PIK3CA inhibitor to have reached the market for breast cancer, having been ...

The park in central Wisconsin is still closed to hikers days after a fire damaged the stairway that leads to the top of Roche ...

RHHBY obtains FDA approval for Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca’s Faslodex for certain breast cancer ...

Black Friday is officially on Friday 29th November, but plenty of the sales will start well before then. In fact, it's worth keeping an eye on the deals for the entire month of November if the past ...

Some trails in the park in central Wisconsin reopened Friday to hikers days after a fire damaged stairway that leads to the ...

Patients with inflammatory bowel disease (IBD) who initially responded to the investigational monoclonal antibody ...